A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 573 participants.

Also called NCT05514535

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 573 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05514535
  • EudraCT 2021-004392-13
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Czechia, Greece, Italy, Portugal, Puerto Rico, Romania, Russia, Slovakia, South Africa, Spain, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05514535. Randomized; no masking; primary purpose treatment. Start 2022-08-29 (actual); primary completion 2025-03-05 (actual). Results posted on 2026-05-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
Condition
Diabetes Mellitus, Type 2
Condition
Obesity
Intervention (Drug)
Semaglutide
Intervention (Drug)
Insuline glargine U100 (reduced)
Intervention (Drug)
Insuline glargine U100 (titrated)
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct05514535
Content hash
7f4dea1c0bd63c0f23e54f3822aa78c27d73285ca46b9383bd79174e1a91898d